<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1843">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05397639</url>
  </required_header>
  <id_info>
    <org_study_id>CTP3S1502HT6</org_study_id>
    <secondary_id>2021-003405-22</secondary_id>
    <nct_id>NCT05397639</nct_id>
  </id_info>
  <brief_title>Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type</brief_title>
  <official_title>A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suven Life Sciences Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suven Life Sciences Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the efficacy, safety, tolerability, and&#xD;
      pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in&#xD;
      participants with dementia of the Alzheimer's type.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study, consisting of 12&#xD;
      weeks of treatment.&#xD;
&#xD;
      Approximately 375 participants will be enrolled at approximately 50 centers worldwide.&#xD;
&#xD;
      Study medication will be administered orally once-daily from Day 1 through Day 85. Screening&#xD;
      will occur within approximately 4 weeks prior to randomization. Following screening&#xD;
      procedures for assessment of inclusion and exclusion criteria, eligible participants will be&#xD;
      randomized into the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2022</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cohen-Mansfield Agitation Inventory (CMAI)</measure>
    <time_frame>From Baseline to Week 12 visit</time_frame>
    <description>Change in CMAI items score aligning to the International Psychogeriatric Association (IPA) agitation criteria domains (physical aggression, excessive motor activity, and verbal aggression). CMAI is a validated 29-item questionnaire to assess agitation. Each item is rated on a 7-point scale ranging from 1 &quot;Never&quot; to 7 &quot;Several times per hour&quot;. Higher scores indicate worsening agitation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGI-C)</measure>
    <time_frame>From Baseline to Week 12 visit</time_frame>
    <description>Change in mADCS-CGI-C. The mADCS-CGI-C is a modification of the ADCS-CGI-C instrument that focuses specifically on agitation. It is a 7-point Likert scale that ranges from marked improvement scored as 1 to marked worsening scored as 7. The range is from 1 to 7. Higher scores indicate worsening agitation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Agitation</condition>
  <condition>Alzheimer's Type Dementia</condition>
  <arm_group>
    <arm_group_label>Low Dose Masupirdine Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Masupirdine Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masupirdine 50 mg</intervention_name>
    <description>Tablet, Once Daily</description>
    <arm_group_label>Low Dose Masupirdine Arm</arm_group_label>
    <other_name>SUVN-502</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masupirdine 100 mg</intervention_name>
    <description>Tablet, Once Daily</description>
    <arm_group_label>High Dose Masupirdine Arm</arm_group_label>
    <other_name>SUVN-502</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo Tablet, Once Daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of dementia of the Alzheimer's type according to the National&#xD;
             Institute on Aging-Alzheimer's Association (NIA-AA) criteria.&#xD;
&#xD;
          -  Has confirmed agitation using the IPA Consensus Provisional Definition of Agitation in&#xD;
             Cognitive Disorders.&#xD;
&#xD;
          -  Has a score between 8 and 24 (both inclusive) on Mini-Mental State Examination (MMSE).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular&#xD;
             dementia, parkinson's disease, lewy body disease, frontotemporal dementia)&#xD;
&#xD;
          -  Has symptoms of agitation that are not secondary to Alzheimer's disease (eg, pain,&#xD;
             other psychiatric disorder, or delirium due to a metabolic disorder, systemic&#xD;
             infection, or substance-induced).&#xD;
&#xD;
          -  Participant (or caregiver) is deemed otherwise ineligible for participation in this&#xD;
             study in the investigator's judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>+9140 2319 3956</phone>
    <email>agitation@suven.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ATP Clinical Research, Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626-4607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Alva</last_name>
      <phone>714-277-4472</phone>
      <email>galva@atpcr.com</email>
    </contact>
    <investigator>
      <last_name>Gustavo Alva</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Alva</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa Flores</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bobby Shih</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Miami Medical Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122-1335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Alonso, MD</last_name>
      <phone>305-547-2011</phone>
      <email>leonardo.alonsomd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Leonardo Alonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magaly Alonso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Ocana</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allied Biomedical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125-2607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pfeffer, MD</last_name>
      <phone>305-643-8400</phone>
      <email>mpfeffer@abriusa.net</email>
    </contact>
    <investigator>
      <last_name>Michael Pfeffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novel Clinical Research Center, LLC.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heber Varela</last_name>
      <phone>786-773-2737</phone>
      <email>hvarela@novelclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Heber Varela</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312-6501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark DiBuono, MD</last_name>
      <phone>718-317-5522</phone>
      <email>dibuono@rbany.com</email>
    </contact>
    <investigator>
      <last_name>Mark DiBuono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Smith</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Priya Selvarajah</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimberly Colangelo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>May 25, 2022</study_first_submitted>
  <study_first_submitted_qc>May 25, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2022</study_first_posted>
  <last_update_submitted>August 30, 2022</last_update_submitted>
  <last_update_submitted_qc>August 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Masupirdine</keyword>
  <keyword>SUVN-502</keyword>
  <keyword>Phase 3</keyword>
  <keyword>Agitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

